



Rancho Los Amigos National Rehabilitation Center

OUTPATIENT SERVICES

POLICY AND PROCEDURE

SUBJECT: Gilenya /Fingolimod –
Initial Dose

Policy No.: 6.02.01

Reviewed: 06/2018

Page: 1 of 1

PURPOSE:

To delineate the procedure for clinical management of patients with Multiple Sclerosis starting the initial dose of Gilenya/Fingolimod. Patients starting the initial course of Gilenya require minimum 6-hour monitoring of vital signs due to potential for temporary decrease of heart rate.

PROCEDURE:

- A. The provider identifies potential Gilenya candidate
 1. Orders assessment tests including EKG, lab, etc.
 2. Provides patient/caregiver education

- B. Provider has identified a candidate to receive Gilenya
 1. Provider obtains DHS approval by submitting the "DHS PRIOR AUTHORIZATION MEDICATION REQUEST FORM".
 - i. DHS Core Pharmacy & Therapeutics Committee approval is required for medications not on the DHS Formulary.
 2. Provider orders initial dose monitoring and post-dose actions
 3. Provider oversees patient/caregiver education regarding monitoring process

- C. Gilenya initial dose:
 1. Appointment is scheduled for Multiple Sclerosis Clinic
 2. Provider is available onsite during procedure to oversight and consultation, as needed
 3. Patient obtains a starter course of medication from RLANRC Pharmacy
 4. Patient rests comfortably in a location designated by clinic staff for at least 6-hours
 5. Heart rate and blood pressure are monitored on an hourly basis or as needed
 6. Patient shall be monitored for additional 1-2 hours if vital signs have not resolved
 7. Post-dose EKG test, as needed

- D. Urgent medical needs shall be managed in accordance with RLANRC policies and procedures

EFFECTIVE DATE: June 2018

COUNTY OF LOS ANGELES • DEPARTMENT OF HEALTH SERVICES

APPROVED BY: Dennis Wong, MD

Signature(s) on File. Leilani Hermosura, NP

Walter Afable, MBA